3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Arboretum Ventures VIFiled to raise in 2022, with no closing reported yet. | 2022 | $250M | $0 | 0 |
| Arboretum Ventures VFiled to raise in 2019, with no closing reported yet. | 2019 | $250M | $0 | 0 |
| Arboretum Ventures IVFiled to raise in 2015, with no closing reported yet. | 2015 | $215M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Dan Kidle | Slowing | None listed | 7 | 1 |
Classified sectors of Arboretum Ventures’s own portfolio companies, based on 11 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Baird Venture Partners | 3 | Allay Therapeutics, NeuMoDx Molecular, Strata Oncology |
| Versant Affiliates | 3 | ADVANCED ICU CARE, FIDELIS SENIORCARE, ViaLase |
| Versant Venture Capital | 3 | ADVANCED ICU CARE, FIDELIS SENIORCARE, ViaLase |
| Thomas Shehab | Slowing | Biotech & pharma, Consumer apps & internet, Medical devices | 8 | 1 |
| Jan Garfinkle | Quiet | Medical devices, Biotech & pharma | 9 | 0 |
| Paul McCreadieNot on the current fund | Quiet | Biotech & pharma, Digital health | 6 | 0 |
| Timothy PetersenNot on the current fund | Quiet | Healthcare services, Biotech & pharma, Digital health | 12 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Arboretum Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 1 |
| SONITUS MEDICAL |
| Bridge Street | 1 | Motif Neurotech |
| BVP | 1 | Strata Oncology |
| Domain Partners | 1 | Allay Therapeutics |
| Highland Capital Partners | 1 | FIDELIS SENIORCARE |
| Lightstone Ventures | 1 | Allay Therapeutics |
| Lux Capital | 1 | Aira Tech |
| MBD | 1 | Motif Neurotech |
| SV Life Sciences | 1 | CERVILENZ |
| U.S Venture Partners | 1 | ViaLase |
| Virtuoso-mccarran | 1 | CERVILENZ |
A shared board seat: a company where filings name a Arboretum Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
